Medpace downgraded by TD Cowen with a new price target
$MEDP
Biotechnology: Commercial Physical & Biological Resarch
Health Care
TD Cowen downgraded Medpace from Buy to Hold and set a new price target of $328.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/22/2025 | Outperform → Mkt Perform | William Blair | |
| 4/14/2025 | $328.00 | Buy → Hold | TD Cowen |
| 3/24/2025 | $330.00 | Market Perform | Leerink Partners |
| 10/23/2024 | $413.00 → $349.00 | Outperform → Neutral | Robert W. Baird |
| 10/14/2024 | Buy | Redburn Atlantic | |
| 9/27/2024 | $420.00 → $350.00 | Buy → Neutral | UBS |
| 9/25/2024 | $415.00 → $345.00 | Buy → Hold | Jefferies |
| 8/1/2024 | $415.00 | Hold | Truist |
8-K - Medpace Holdings, Inc. (0001668397) (Filer)
144 - Medpace Holdings, Inc. (0001668397) (Subject)
10-Q - Medpace Holdings, Inc. (0001668397) (Filer)
Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were $500.0 million in the first quarter of 2025, representing a decrease of 18.8% from net new business awards of $615.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.90x. First quarter of 2025 GAAP net income was $114.6 million, or $3.67 per diluted share, versus GAAP net income of $102.6 million, or $3.20 per diluted share, for the comparable prior-year period. Net income margin was 20.5% and 20.1% for the first quarter of 2025
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, 2025. The Company will host a conference call the following morning, Tuesday, April 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used
Revenue of $536.6 million in the fourth quarter of 2024 increased 7.7% from revenue of $498.4 million for the comparable prior-year period, representing a backlog conversion rate of 18.3%. Net new business awards were $529.7 million in the fourth quarter of 2024, representing a decrease of 13.8% from net new business awards of $614.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.99x. Fourth quarter of 2024 GAAP net income was $117.0 million, or $3.67 per diluted share, versus GAAP net income of $78.3 million, or $2.46 per diluted share, for the comparable prior-year period. Net income margin was 21.8% and 15.7% for the fourth quarter of
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
William Blair downgraded Medpace from Outperform to Mkt Perform
TD Cowen downgraded Medpace from Buy to Hold and set a new price target of $328.00
Leerink Partners initiated coverage of Medpace with a rating of Market Perform and set a new price target of $330.00
Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. August Troendle will continue to serve as Medpace's chairman and chief executive officer. Geiger joined Medpace in 2007 as corporate controller and became chief financial officer in 2011. In 2014, Geiger expanded his role to include chief operating officer of laboratory operations. Geiger will continue to report to August Troendle. The newly created position of president will allow Troendle to continue to focus on the overall lon
Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were $500.0 million in the first quarter of 2025, representing a decrease of 18.8% from net new business awards of $615.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.90x. First quarter of 2025 GAAP net income was $114.6 million, or $3.67 per diluted share, versus GAAP net income of $102.6 million, or $3.20 per diluted share, for the comparable prior-year period. Net income margin was 20.5% and 20.1% for the first quarter of 2025
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, 2025. The Company will host a conference call the following morning, Tuesday, April 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used
Revenue of $536.6 million in the fourth quarter of 2024 increased 7.7% from revenue of $498.4 million for the comparable prior-year period, representing a backlog conversion rate of 18.3%. Net new business awards were $529.7 million in the fourth quarter of 2024, representing a decrease of 13.8% from net new business awards of $614.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.99x. Fourth quarter of 2024 GAAP net income was $117.0 million, or $3.67 per diluted share, versus GAAP net income of $78.3 million, or $2.46 per diluted share, for the comparable prior-year period. Net income margin was 21.8% and 15.7% for the fourth quarter of
SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)